LearnSkin
Course Image: The Use of Systemic Medications in Psoriasis and Psoriatic Arthritis
The Use of Systemic Medications in Psoriasis and Psoriatic Arthritis
Tina Bhutani, MD MAS
Supported by independent educational grants from Janssen Biotech, Inc and UCB

Many systemic therapies are now available for use in psoriasis and psoriatic arthritis and include the use of biologics and oral medications. This includes specific targeting of TNF and the IL-17/IL-23 pathways as well as the emergence of oral JAK and TYK2 inhibitors. The role of phototherapy will be discussed. 

Learning Objectives:

  • Participants will identify when systemic therapies are indicated for the treatment of psoriasis and how phototherapy may be included.
  • Participants will compare and describe the efficacy for the use of systemic medications for psoriasis including selective inhibition of IL-17A, dual inhibition of IL-17A and IL-17F, Il-23 inhibitors, and TYK2 inhibition.
  • Participants will discuss the evidence for the safety of IL-17, IL-23, JAK and TYK2 inhibitors including the risk for boxed warnings such as suicide, malignancy, and thromboses. 

Faculty

Tina Bhutani-Jacques
Tina Bhutani
MD MAS

Dr. Tina Bhutani is a board certified dermatologist and clinical researcher practicing in San Francisco, California. She received her medical training at the University of Southern California Keck School of Medicine and completed her residency in dermatology at UCSF. Dr. Bhutani has an expertise in the treatment of psoriasis, atopic dermatitis, and other inflammatory skin diseases. In addition to seeing patients, she is a Associate Adjunct Professor in the Department of Dermatology at UCSF. She is passionate about improving the care and lives of patients with inflammatory skin disorders and is involved in many studies focusing on the development of new treatments for these diseases and learning more about mechanisms of disease initiation and maintenance. She has a particular interest in the impact of disease on patient quality of life and mental health as well as the use of wellness-based behavior modification to improve disease severity and reduce the risk of associated comorbidities. She has published over 150 articles in peer-reviewed journals and has spoken at national and international conferences on these topics. She is a member of the National Psoriasis Foundation (NPF) Scientific Advisory committee and has received research grant funding from the NPF, the Dermatology Foundation, as well as Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). She also serves as the current editor-in-chief for the journal Psoriasis: Targets and Therapy. 

View Bio

Editors

User: jasonhawkes@learnskin.com
Jason Ezra Hawkes
MD MS FAAD

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, Oregon. He completed his medical school and residency at the University of Utah. During medical school, he completed a fellowship in translational immunology in the NIH-HHMI Research Scholars Program. He also received a Master’s Degree in Clinical Investigation from Rockefeller University, where he was Chief Clinical Scholar and Principal and sub-Investigator on multiple human research protocols in the Laboratory for Investigative Dermatology. He has held academic appointments in the Departments of Dermatology at the University of Utah, University of California-Davis, Icahn School of Medicine at Mount Sinai.

Dr. Hawkes is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee. He also serves as the official delegate of the AAD as a member of the international guidelines and workgroup committee for urticaria. His research has been funded by the NIH, NSF, NPF, and Dermatology Foundation, and he is the recipient of several teaching awards including NPF Outstanding Educator in Psoriatic Disease and Exceptional Teacher of the Year in the Department of Dermatology at Mount Sinai. His primary clinical and research interests include novel immune therapies for inflammatory conditions like psoriasis, atopic dermatitis, HS, alopecia areata, vitiligo, and urticaria.

View Bio

Related Courses

LearnSkin Logo
All material on this website is protected by copyright. Copyright © LearnHealth Inc. 2024.
This website also contains material copyrighted by 3rd parties.
ABOUT
LEGAL
SUBSCRIBE
To Get Posts Directly In Your Inbox!